A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

Aging brings wisdom, experience, and often, a host of changes — including those that affect our vision. "By the time most people reach their forties, the eye begins to undergo physiological ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

Diabetes is becoming a big health problem in India, but many people don’t even know they have it. A study says 4 out of 10 ...

An Editorial in The Lancet Neurology emphasised that rigorous prospective studies are essential to develop safe and ethical artificial intelligence (AI) tools for brain health.1 Yet, what usually ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

Eye floaters, those drifting spots in your vision, are often harmless but can signal hypertension or diabetes. High blood ...